Nivolumab

Drug Profile

Nivolumab

Alternative Names: Anti-PD-1 monoclonal antibody - Medarex/Ono; BMS-936558; MDX-1106; Nivolumab BMS; ono-0123; ONO-4538; Opdivo

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator Medarex; Ono Pharmaceutical
  • Developer AIO Studien gGmbH; Bristol-Myers Squibb; Duke University Medical Center; Eli Lilly; Grupo Espanol Multidisciplinar de Melanoma; Incyte Corporation; Janssen Research & Development; Kyoto University; Kyowa Hakko Kirin; Medarex; National Cancer Institute (USA); Nektar Therapeutics; Neon Therapeutics; Netherlands Cancer Institute; Ono Pharmaceutical; Pharmacyclics; Seattle Genetics; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Hodgkin's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma
  • Registered Head and neck cancer; Hodgkin's disease
  • Preregistration Urogenital cancer
  • Phase III Gastric cancer; Glioblastoma; Hepatocellular carcinoma; Mesothelioma; Multiple myeloma; Oesophageal cancer; Small cell lung cancer
  • Phase II Acute myeloid leukaemia; Breast cancer; Cancer; Cervical cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Myelodysplastic syndromes; Ovarian cancer; Soft tissue sarcoma; Uterine cancer; Uveal melanoma
  • Phase I/II Colorectal cancer; Haematological malignancies; Non-Hodgkin's lymphoma; Solid tumours
  • Phase I Biliary cancer; Bladder cancer; Chronic myeloid leukaemia; Glioma; Hepatitis C

Most Recent Events

  • 05 Jan 2017 Jonsson Comprehensive Cancer Center and National Cancer Institute plan a phase II trial for Glioblastoma (Combination therapy, Recurrent) in USA (IV) (NCT03014804)
  • 05 Jan 2017 Janssen Biotech and Bristol-Myers Squibb enter into a clinical trial agreement for daratumumab plus nivolumab in Multiple myeloma and Solid tumours
  • 05 Jan 2017 Janssen Biotech and Bristol-Myers Squibb plan phase Ib/II trials for daratumumab plus nivolumab in Multiple myeloma and Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top